Nevro to Present at Canaccord Genuity 40th Annual Virtual Growth Conference

Nevro Corp. (NYSE: NVRO), a medical device company focused on chronic pain solutions, will present at the Canaccord Genuity 40th Annual Virtual Growth Conference on August 13, 2020, at 3:30 PM ET.

Rhea-AI Summary

Nevro Corp. (NYSE: NVRO), a medical device company focused on chronic pain solutions, will present at the Canaccord Genuity 40th Annual Virtual Growth Conference on August 13, 2020, at 3:30 PM ET. CEO D. Keith Grossman will lead the presentation. A live webcast can be accessed on Nevro's website, with a replay available for 30 days afterward. Nevro's innovative Senza spinal cord stimulation system provides a non-pharmacologic approach to managing chronic pain, showing that HF10 therapy can reduce or eliminate opioids in over 65% of patients in clinical studies.

Argus Session date unavailable

-0.50% session move Open Argus

Details

News Market Reaction – NVRO

The recorded move for NVRO in the trading session of this news was -0.50%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Aug. 7, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the Canaccord Genuity 40^th Annual Virtual Growth Conference on August 13, 2020, beginning at approximately 3:30 pm Eastern Time.

A live webcast of this event will be available on the Investors section of Nevro's website at www.nevro.com.  A webcast replay will be available approximately one hour after the live webcast ends and will be accessible for approximately 30 days.

About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain.  Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza^® System, Senza II™ System, and the Senza^® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10^® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp. 

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investor Relations:
Juliet Cunningham
Vice President, Investor Relations
+1 650-433-3247
ir@nevro.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-to-present-at-canaccord-genuity-40th-annual-virtual-growth-conference-301108267.html

SOURCE Nevro Corp.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Nevro present at the Canaccord Genuity Virtual Growth Conference?

Nevro will present on August 13, 2020, at 3:30 PM ET.

Who will represent Nevro at the conference?

D. Keith Grossman, Nevro's Chairman, CEO, and President, will lead the presentation.

Where can I watch Nevro's conference presentation?

The presentation will be available via live webcast on Nevro's website.

What is the main focus of Nevro's products?

Nevro focuses on innovative medical devices to treat chronic pain with evidence-based solutions.

What results have been shown from Nevro's HF10 therapy?

HF10 therapy has demonstrated the ability to reduce or eliminate opioids in over 65% of patients in clinical studies.